JP2007510662A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007510662A5 JP2007510662A5 JP2006538496A JP2006538496A JP2007510662A5 JP 2007510662 A5 JP2007510662 A5 JP 2007510662A5 JP 2006538496 A JP2006538496 A JP 2006538496A JP 2006538496 A JP2006538496 A JP 2006538496A JP 2007510662 A5 JP2007510662 A5 JP 2007510662A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- compound
- heteroaryl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 38
- 125000003118 aryl group Chemical group 0.000 claims 31
- 125000001072 heteroaryl group Chemical group 0.000 claims 23
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims 6
- 206010012601 diabetes mellitus Diseases 0.000 claims 6
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 1
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 101150065749 Churc1 gene Proteins 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 102100038239 Protein Churchill Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000000923 atherogenic effect Effects 0.000 claims 1
- 125000004188 dichlorophenyl group Chemical group 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000005936 piperidyl group Chemical group 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51705803P | 2003-11-04 | 2003-11-04 | |
| PCT/US2004/036870 WO2005046682A1 (en) | 2003-11-04 | 2004-11-04 | Therapeutic compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007510662A JP2007510662A (ja) | 2007-04-26 |
| JP2007510662A5 true JP2007510662A5 (enExample) | 2007-11-29 |
Family
ID=34590135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538496A Withdrawn JP2007510662A (ja) | 2003-11-04 | 2004-11-04 | 治療化合物およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7504506B2 (enExample) |
| EP (1) | EP1682136A4 (enExample) |
| JP (1) | JP2007510662A (enExample) |
| CN (1) | CN1901908A (enExample) |
| CA (1) | CA2544602A1 (enExample) |
| MX (1) | MXPA06005038A (enExample) |
| WO (1) | WO2005046682A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3856815B2 (ja) | 2003-04-04 | 2006-12-13 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体アゴニストとしてのアシル化スピロピペリジン誘導体 |
| WO2005097788A2 (en) * | 2004-04-02 | 2005-10-20 | Elixir Pharmaceuticals, Inc. | Sulfonamides and uses thereof |
| US20090275648A1 (en) * | 2005-06-13 | 2009-11-05 | Fraser Graeme L | Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
| EP3586846A1 (en) | 2005-09-29 | 2020-01-01 | Ipsen Pharma | Compositions and methods for stimulating gastrointestinal motility |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| KR100764640B1 (ko) * | 2006-03-08 | 2007-10-10 | 세원셀론텍(주) | 지방조직 수복용 키트 |
| WO2008068185A1 (en) | 2006-12-07 | 2008-06-12 | F. Hoffmann-La Roche Ag | Spiro-piperidine derivatives as via receptor antagonists |
| JP2010513384A (ja) | 2006-12-22 | 2010-04-30 | エフ．ホフマン−ラ ロシュ アーゲー | スピロ−ピペリジン誘導体 |
| JP2010515700A (ja) | 2007-01-12 | 2010-05-13 | エフ．ホフマン−ラ ロシュ アーゲー | スピロピペリジングリシンアミド誘導体 |
| BRPI0807046A2 (pt) | 2007-02-09 | 2015-05-26 | Tranzyme Pharma Inc | Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit. |
| US20100022572A1 (en) | 2008-07-18 | 2010-01-28 | Kowa Company, Ltd. | Novel spiro compound and medicine comprising the same |
| CN102224254A (zh) * | 2008-09-23 | 2011-10-19 | 哈佛大学校长及研究员协会 | Sirt4及其用途 |
| WO2010050191A1 (ja) | 2008-10-29 | 2010-05-06 | 興和株式会社 | １，２－ジアゼチジン－３－オン誘導体及びこれを含有する医薬 |
| EP2483406A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products |
| AR078522A1 (es) * | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| US20110105389A1 (en) | 2009-10-30 | 2011-05-05 | Hoveyda Hamid R | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same |
| AR078948A1 (es) | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
| WO2013119800A1 (en) | 2012-02-07 | 2013-08-15 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| WO2014144231A1 (en) | 2013-03-15 | 2014-09-18 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
| JP6712230B2 (ja) * | 2014-03-11 | 2020-06-17 | ノバルティス アーゲー | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
| WO2016138099A1 (en) | 2015-02-24 | 2016-09-01 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
| US20230357140A1 (en) * | 2020-09-23 | 2023-11-09 | Translate Bio, Inc. | Tes-based cationic lipids |
| KR20230145454A (ko) * | 2021-04-25 | 2023-10-17 | 장춘 진사이언스 파마슈티컬 씨오., 엘티디. | 인돌린 함유 스피로 고리 유도체, 그 제조 방법 및 의약에서의 응용 |
| PE20250603A1 (es) | 2022-01-18 | 2025-02-26 | Maze Therapeutics Inc | Inhibidores de apol1 y metodos de uso |
| WO2024083164A1 (zh) * | 2022-10-21 | 2024-04-25 | 长春金赛药业有限责任公司 | 吲哚啉螺环类化合物的溶剂化物及其晶型、制备方法和应用 |
| KR20250069665A (ko) * | 2022-10-21 | 2025-05-19 | 장춘 진사이언스 파마슈티컬 씨오., 엘티디. | 인돌린 스피로계 화합물의 결정형, 무정형물 및 양자의 제조 방법 및 적용 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5536716A (en) * | 1992-12-11 | 1996-07-16 | Merck & Co., Inc. | Spiro piperidines and homologs which promote release of growth hormone |
| RO115804B1 (ro) | 1992-12-11 | 2000-06-30 | Merck & Co Inc | Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora |
| US5492916A (en) | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| US5494919A (en) | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| US5492920A (en) | 1993-12-10 | 1996-02-20 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
| US5721251A (en) | 1993-12-10 | 1998-02-24 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
| US5721250A (en) | 1993-12-23 | 1998-02-24 | Merck & Co. Inc. | Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| AU3128195A (en) | 1994-07-20 | 1996-02-16 | Merck & Co., Inc. | Piperidines and hexahydro-1h-azepines spiro substituted at the 4-position promote release of growth hormone |
| US5559128A (en) | 1995-04-18 | 1996-09-24 | Merck & Co., Inc. | 3-substituted piperidines promote release of growth hormone |
| US5767124A (en) | 1995-10-27 | 1998-06-16 | Merck & Co., Inc. | Polymorphic forms of a growth hormone secretagogue |
| US5723616A (en) * | 1995-10-27 | 1998-03-03 | Merck & Co., Inc. | Process for the preparation of a growth hormone secretagogue |
| WO1997022367A1 (en) | 1995-12-20 | 1997-06-26 | Merck & Co., Inc. | Radiolabeled growth hormone secretagogue |
| GB9612276D0 (en) | 1996-06-12 | 1996-08-14 | Merck & Co Inc | 4-Spiroindoline piperidines promote release of growth hormone |
| US5877182A (en) | 1996-09-13 | 1999-03-02 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
| US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
| AU767433B2 (en) | 1999-07-13 | 2003-11-13 | Merck Sharp & Dohme Corp. | Amido spiropiperidines promote the release of growth hormone |
| WO2005097788A2 (en) * | 2004-04-02 | 2005-10-20 | Elixir Pharmaceuticals, Inc. | Sulfonamides and uses thereof |
-
2004
- 2004-11-04 MX MXPA06005038A patent/MXPA06005038A/es not_active Application Discontinuation
- 2004-11-04 JP JP2006538496A patent/JP2007510662A/ja not_active Withdrawn
- 2004-11-04 CA CA002544602A patent/CA2544602A1/en not_active Abandoned
- 2004-11-04 CN CNA2004800397133A patent/CN1901908A/zh active Pending
- 2004-11-04 EP EP04800764A patent/EP1682136A4/en not_active Withdrawn
- 2004-11-04 WO PCT/US2004/036870 patent/WO2005046682A1/en not_active Ceased
- 2004-11-04 US US10/982,997 patent/US7504506B2/en not_active Expired - Fee Related
-
2009
- 2009-02-09 US US12/367,585 patent/US7897765B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007510662A5 (enExample) | ||
| JP2008525416A5 (enExample) | ||
| JP2005507872A5 (enExample) | ||
| EP1325921A3 (en) | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | |
| JP2007533741A5 (ja) | Ｂａｃｅ阻害剤として有用なピロリジン誘導体 | |
| JP2011519910A5 (enExample) | ||
| JP2007508359A5 (enExample) | ||
| JP2008526724A5 (enExample) | ||
| JP2005053931A5 (enExample) | ||
| JP2010526814A5 (enExample) | ||
| JP2002513793A5 (enExample) | ||
| JP2009534468A5 (enExample) | ||
| JP2007519721A5 (enExample) | ||
| JP2011513305A5 (enExample) | ||
| JP2011527334A5 (enExample) | ||
| JP2005112864A5 (enExample) | ||
| JP2004525150A5 (enExample) | ||
| JP2005539088A5 (enExample) | ||
| JP2008505117A5 (enExample) | ||
| JP2006509015A5 (enExample) | ||
| JP2007531739A5 (enExample) | ||
| JP2007527909A5 (enExample) | ||
| JP2011516511A5 (enExample) | ||
| JP2007502817A5 (enExample) | ||
| DE602006009095D1 (en) | Diacylglycerol-acyltransferase-hemmer |